[HTML][HTML] Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell …

J Styczynski, W van der Velden, CP Fox… - …, 2016 - ncbi.nlm.nih.gov
Epstein-Barr virus-related post-transplant lymphoproliferative disorders are recognized as a
significant cause of morbidity and mortality in patients undergoing hematopoietic stem cell …

Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies

C Chabannon, J Kuball, A Bondanza, F Dazzi… - Science translational …, 2018 - science.org
Over the last 60 years, more than a million patients received hematopoietic cell
transplantation. Having incorporated multiple changes in clinical practices, it remains a …

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

S Prockop, E Doubrovina, S Suser… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes
(EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of …

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of …

H Torikai, A Reik, PQ Liu, Y Zhou… - Blood, The Journal …, 2012 - ashpublications.org
Clinical-grade T cells are genetically modified ex vivo to express a chimeric antigen receptor
(CAR) to redirect specificity to a tumor associated antigen (TAA) thereby conferring antitumor …

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT

A Papadopoulou, U Gerdemann, UL Katari… - Science translational …, 2014 - science.org
It remains difficult to treat the multiplicity of distinct viral infections that afflict
immunocompromised patients. Adoptive transfer of virus-specific T cells (VSTs) can be safe …

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

E Doubrovina, B Oflaz-Sozmen… - Blood, The Journal …, 2012 - ashpublications.org
We evaluated HLA-compatible donor leukocyte infusions (DLIs) and HLA-compatible or HLA-
disparate EBV-specific T cells (EBV-CTLs) in 49 hematopoietic cell transplantation …

Adoptive immunotherapy for cancer or viruses

MV Maus, JA Fraietta, BL Levine… - Annual review of …, 2014 - annualreviews.org
Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the
treatment of cancer and certain chronic viral infections. The application of the principles of …

T cells for viral infections after allogeneic hematopoietic stem cell transplant

CM Bollard, HE Heslop - Blood, The Journal of the American …, 2016 - ashpublications.org
Despite recent advances in the field of allogeneic hematopoietic stem cell transplantation
(HSCT), viral infections are still a major complication during the period of immune …

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

M Neuenhahn, J Albrecht, M Odendahl, F Schlott… - Leukemia, 2017 - nature.com
Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication
following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed …

Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus–related lymphoproliferative disorder after hematopoietic stem cell transplant in …

J Styczynski, L Gil, G Tridello… - Clinical infectious …, 2013 - academic.oup.com
Background. The objective of this analysis was to investigate prognostic factors that
influence the outcome of Epstein-Barr virus (EBV)–related posttransplant lymphoproliferative …